Breaking News

SAFC, BioTools Enter Technology Pact

May 7, 2014

Will align Pharmorphix and BioTools for comprehensive chiral technology services

Sigma-AldrichCorp.’s custom manufacturing and services business unit, SAFC Commercial, has entered into a collaborative technology agreement with BioTools, Inc. to combine its advanced chiroptical spectroscopic instruments with SAFC’s solid-state R&D business, Pharmorphix. The combined services will offer access to a comprehensive range of chiral structural determination tools and separation services aimed at accelerating timelines for chiral-based drugs.
Pharmorphix solid state technologies will contribute the application of powder and single-crystal X-ray diffraction technology, including chiral structure determination of small molecules and enantioselective resolution services using crystallization and chromatography. BioTools will apply its instruments and software, including ChiralIR-2X, ChiralRAMAN-2X, ComputeVOA and CompareVOA, to determine the configuration of chiral compounds required for regulatory IND submissions of pharmaceuticals.
“Our partnership with BioTools enables customers to approach a single service provider to get access to the highest levels of efficiency and confidence in structural determination, including the configuration of chiral structures,” said Dr. Chris Frampton, chief scientific officer at SAFC’s Pharmorphix Solid State Research Laboratories. “This extended range of structural and chiral separation solutions will play an important role in accelerating the drug discovery and development process.”
“The alignment of knowledge, experienced staff, and advanced instrumentation and software creates a formidable force to effectively help researchers meet the complex challenges of chiral drug development,” added BioTools president Dr. Rina Dukor.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016